Skip to main content

Simultaneous Use of Percutaneous Aspiration (AngioVac) and Transcatheter Mitral Valve-in-Valve Intervention for Mitral Valve Vegetation

The full content of this page is available to users only after login from the link

In July 2022, medical professionals from the University of Arkansas for Medical Sciences reported a case of mitral valve bioprosthesis failure due to significant vegetation successfully treated with percutaneous aspiration (AngioVac) evacuation followed by MViV intervention. The complete report by Jack Xu, Shravan Turaga, Jay Bhama, Srikanth Vallurupalli, and Gaurav Dhar can be found in Methodist DeBakey Cardiovascular Journal. The summary of their report is detailed below.

Mitral valve replacement is most often completed with bioprosthetic valves; however, they possess limited durability, and when operating on a failed bioprosthetic again, morbidity and mortality increase. Therefore, transcatheter mitral valve-in-valve (MViV) replacements using a transseptal approach are used more often because of their high technical success and low risk of complication. In addition, for patients at high surgical risk, the use of the AngioVac transcatheter aspiration system (Angiodynamics) for a minimally invasive technique is increasing in popularity, especially to debulk vegetation, tumors, or thrombi on the right side.